PGP9.5 methylation in diffuse-type gastric cancer

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3921-3927

  Yamashita, Keishi ^a   Park, Hannah Lui ^a   Kim, Myoung Sook ^a   Osada, Motonobu ^a   Tokumaru, Yutaka ^a   Inoue, Hiroshi ^b   Mori, Masaki ^b   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTOPLASM PROTEIN; PROTEIN PGP9 5; RNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); STOMACH NEOPLASMS; UBIQUITIN THIOLESTERASE;

EID: 33645736546     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1511     Document Type: Article

References (46)

1. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell 2004;5:121-5.
2. Ridley A. Molecular switches in metastasis. Nature (Lond) 2000;406:466-7.
3. Hermanek P. Prognostic factors in stomach cancer surgery. Eur J Surg Oncol 1986;12:241-6.
4. Wu M, Yang K, Shun C, et al. Distinct clinicopathologic characteristics of diffuse- and intestinal-type gastric cancer in Taiwan. J Clin Gastroenterol 1997;25:646-9.
5. Yawata A, Adachi M, Okuda H, et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 1998;16:2681-6.
6. Kobayashi M, Nagata S, Iwasaki T, et al. Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3- kinase. Proc Natl Acad Sci U S A 1999;96:4874-9.
7. Ishii Y, Ochiai A, Yamada T, et al. Integrin alpha6beta4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer. Gastroenterology 2000;118:497-506.
8. Nishimura S, Adachi M, Ishida T, et al. Adenovirus-mediated transfection of caspase-8 augments anoikis and inhibits peritoneal dissemination of human gastric carcinoma cells. Cancer Res 2001;61:7009-14.
9. Elster K, Carson W, Wild A, Thomasko A. Evaluation of histological classification in early gastric cancer (an analysis of 300 cases). Endoscopy 1979;11:203-6.
10. Teh M, Lee Y. Intestinal and diffuse carcinoma of the stomach among the ethnic and dialect groups in Singapore. Cancer 1987;60:921-5.
11. Janssen C, Jr., Maartmann-Moe H, Lie R, Matre R. Age and sex distribution of intestinal and diffuse type carcinoma. APMIS 1991;99:78-82.
12. Zanghieri G, Di Gregorio C, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of population-based registry. Cancer 1990;66:2047-51.
13. Becker K, Atkinson M, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-52.
14. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5.
15. Machando J, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter hypermethylation as the second hit in sporadic diffuse type gastric carcinoma. Oncogene 2001;20:1525-8.
16. Grady W, Willis J, Guilford P, et al. Methylation of the CDH1 promoter as the second genetic hereditary diffuse gastric cancer. Nat Genet 2000;26:16-7.
17. Tamura G, Yin J, Wang S, et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000;92:569-73.
18. Hoque M, Begum S, Topalogu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511-7.
19. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
20. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth suppression activity. Nat Genet 2001;28:29-35.
21. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
22. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
23. Yamashita K, Upadhyay S, Osada M, et al. Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
24. Tokumaru Y, Yamashita K, Osada M, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004;64:5982-7.
25. Mandelker D, Yamashita K, Tokumaru Y, et al. PGP9.5 Promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005;65:4963-8.
26. Honda T, Tamura G, Waki T, et al. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002;93:857-60.
27. Cimerman M, Repse S, Jelene F, et al. Comparison of Lauren's, Ming's and WHO histological classifications of gastric cancer as a prognostic factor for operative patients. Int Surg 1994;79:27-32.
28. Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000;89:1418-24.
29. Rohde H, Bauer P, Stutzer H, Heitmann K, Gebbensleben B. Proximal compared with distal adenocarcinoma of the stomach: differences and consequences. German Gastric Cancer TNM Study Group. Br J Surg 1991;78:1242-8.
30. Skinner J, Whitehead R. Tumor markers in carcinoma and premalignant states of the stomach in humans. Eur J Cancer Clini Oncol 1982;18:227-35.
31. Fiocca R, Villani L, Tenti P, et al. The foveolar cell component of gastric cancer. Hum Pathol 1990;21:260-70.
32. Teh M, Lee Y. HLA-DR antigen expression in intestinal-type and diffuse-type gastric carcinoma. Cancer 1992;69:1104-7.
33. Hurlimann J, Saraga E. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994;18:1247-53.
34. Lin J, Wu M, Shun C, et al. Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB2 oncoprotein. Cancer Res 1995;55:1428-30.
35. Fricke E, Keller G, Becker I, et al. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse type gastric carcinoma. Int J Cancer 2003;104:60-5.
36. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
37. Yamashita K, Mimori M, Inoue H, Mori M, Sidransky D. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 2003;63:6575-8.
38. Douglas D, Akiyama Y, Carraway H, et al. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 2004;64:1611-20.
39. Oda T, Kanai Y, Oyama T, et al. E-cadherin gene mutation in human gastric carcinoma cell lines. Proc Natl Acad Sci U S A 1994;91:1858-62.
40. Cameron E, Bachman K, Myohanen S, Herman J, Baylin S. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancers. Nat Genet 1999;21:103-7.
41. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
42. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
43. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
44. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52.
45. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-5.
46. Harden S, Sanderson H, Goodman S, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95:1634-7.